A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide, and MK-421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension.
Enalapril and enalapril/hydrochlorothiazide are effective in treating mild to moderate essential hypertension, and efficacy has been demonstrated for up to 48 weeks. The frequency of adverse clinical effects was similar in all three treatment groups, and serious adverse clinical effects were rare.
D000328:Adult; D001741:Black or African American; D000368:Aged; D000704:Analysis of Variance; D001794:Blood Pressure / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000378:metabolism; D011507:Proteinuria / Q000378:metabolism; D011897:Random Allocation; D012965:Sodium Chloride / Q000378:metabolism
D006852:Hydrochlorothiazide; D012965:Sodium Chloride; D004656:Enalapril; D011188:Potassium